Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELENE 2: AZD6234 in adults with overweight or obesity and type 2 diabetes
jRCT2031260465Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2026
- Modality
- Peptides
01
Overview
Randomised, double-blind trial of lenbelintide in obesity, Overweight and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Percent change in body weight from baseline at 68 weeks of treatment. Started Sep 2026; status: recruiting.
02
Drugs
lenbelintide
03
Conditions
obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031260465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260465.